Chronic renal disease, inflammation and atherosclerosis: New concepts about an old problem;Doença renal crônica, inflamação e aterosclerose: Novos conceitos de um velho problema

Revista da Associacao Medica Brasileira

Volumn 53, Issue 5, 2007, Pages 446-450

  Dummer, Claus Dieter ^a,b   Thomé, Fernando Saldanha ^a   Veronese, Francisco Veríssimo ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Atherosclerosis; Cardiovascular disease; Chronic kidney disease; Inflammation; Oxidative stress

Indexed keywords

EID: 36448990847     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302007000500022     Document Type: Review

References (51)

1. Sociedade Brasileira de Nefrologia. Disponível em: http//www.sbn.org.br. [citado maio 2006].
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl 3):S112-9.
3. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293(14):1737-45.
4. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif. 2001;19(1):53-61.
5. Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant. 2003;18(1):113-9.
6. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology. 2006;11(1):36-41.
7. Stenvinkel P, Heimburger O, Jogestrand T, Karnell A, Samuelsson A. Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure? Kidney Int. 1999;55(6):2531-2.
8. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol. 2001;12(7):1549-57.
9. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340(2):115-26.
10. Lawson JA, Lazarus R, Kelly JJ. Prevalence and prognostic significance of malnutrition in chronic renal insufficiency. J Ren Nutr. 2001;11(1):16-22.
11. Bergstrom J., Lindhom B. Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? Kidney Int. 1993;43:439-550.
12. Lim VS, Kopple JD. Protein metabolism in patients with chronic renal failure: Role of uremia and dialysis. Kidney Int. 2000;58:1-10.
13. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000;15(7):953-60.
14. Bergstrom J, Lindholm B. Malnutrition, cardiac disease, and mortality: an integrated point of view. Am J Kidney Dis. 1998;32(5):834-41.
15. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42(5):864-81.
16. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant. 2004;19(6):1507-19.
17. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35(3):469-76.
18. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68(2):766-72.
19. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 1998;31(1):93-100.
20. Bergstrom J. Mechanisms of uremic suppression of appetite. J Ren Nutr. 1999;9(3):129-32.
21. Axelsson J, Heimburger O, Stenvinkel P. Adipose tissue and inflammation in chronic kidney disease. Contrib Nephrol. 2006;151:165-74.
22. Stenvinkel P, Pecoits-Filho R, Lindholm B. Gene polymorphism association studies in dialysis: the nutrition-inflammation axis. Semin Dial. 2005;18(4):322-30.
23. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212.
24. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38(2-3):189-97.
25. Nascimento MM, Pecoits-Filho R, Qureshi AR, Hayashi SY, Manfro RC, Pachaly MA, et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant. 2004;19(11):2803-9.
26. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158(3):1039-51.
27. Koenig W. Update on C-reactive protein as a risk marker in cardiovascular disease. Kidney Int Suppl. 2003; 84(1):S58-61.
28. Prinsen BH, Rabelink TJ, Beutler JJ, Kaysen GA, De Boer J, Boer WH, et al. Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int. 2003;64(4):1495-504.
29. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89(8):901-8.
30. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41(6):1212-8.
31. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl. 2002;80(3):103-8.
32. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24(5):469-73.
33. Miyata T, Kurokawa K, van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int Suppl. 2000;76(2):S120-5.
34. Drueke TB, Nguyen Khoa T, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl. 2001;78(2):S114-9.
35. Nagase S, Aoyagi K, Hirayama A, Gotoh M, Ueda A, Tomida C, et al. Decreased serum antioxidant activity of hemodialysis patients demonstrated by methylguanidine synthesis and microsomal lipid peroxidation. Nephron. 1996;74(3):555-60.
36. Quinn MT, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc Natl Acad Sci USA. 1985;82(17):5949-53.
37. Horkko S, Savolainen MJ, Kervinen K, Kesaniemi YA. Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int. 1992;41(5):1175-81.
38. a, Pinhais. Programa e Resumos, São Paulo: FESBE, 2003. [CD-ROM].
39. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int Suppl. 2001;78(1):S25-31.
40. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest. 1994;93(2):521-8.
41. Hangaishi M, Taguchi J, Miyata T, Ikari Y, Togo M, Hashimoto Y, et al. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Commun. 1998;248(2):285-92.
42. Satoh H, Togo M, Hara M, Miyata T, Han K, Maekawa H, et al. Advanced glycation endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells. Biochem Biophys Res Commun. 1997;239(1):111-5.
43. Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med. 1999;27(9-10):916-21.
44. Del Maestro RF. An approach to free radicals in medicine and biology. Acta Physiol Scand Suppl. 1980;492(1):153-68.
45. Mimic-Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol. 1999;51(4):233-41.
46. Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res. 1991;68(4):1027-34.
47. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84(24):9265-9.
48. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005;26(1-2):33-65.
49. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88(11):4651-5.
50. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95(1):187-94.
51. Lodha S, Dani D, Mehta R, Bhaskaran M, Reddy K, Ding G, et al. Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol Med. 2002;8(12):830-40.